title: Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.
abstract: A fundamental problem in studying the latent-to-lytic switch of Epstein-Barr virus (EBV) and the viral lytic cycle itself is the lack of a culture system fully permissive to lytic cycle induction. Strategies to target EBV-positive tumors by inducing the viral lytic cycle with chemical agents are hindered by inefficient responses to stimuli. In vitro, even in the most susceptible cell lines, more than 50% of cells latently infected with EBV are refractory to induction of the lytic cycle. The mechanisms underlying the refractory state are not understood. We separated lytic from refractory Burkitt lymphoma-derived HH514-16 cells after treatment with an HDAC inhibitor, sodium butyrate. Both refractory- and lytic-cell populations responded to the inducing stimulus by hyperacetylation of histone H3. However, analysis of host cell gene expression showed that specific cellular transcripts Stat3, Fos, and interleukin-8 (IL-8) were preferentially upregulated in the refractory-cell population, while IL-6 was upregulated in the lytic population. STAT3 protein levels were also substantially increased in refractory cells relative to untreated or lytic cells. This increase in de novo expression resulted primarily in unphosphorylated STAT3. Examination of single cells revealed that high levels of STAT3 were strongly associated with the refractory state. The refractory state is manifest in a unique subpopulation of cells that exhibits different cellular responses than do lytic cells exposed to the same stimulus. Identifying characteristics of cells refractory to lytic induction relative to cells that undergo lytic activation will be an important step in developing a better understanding of the regulation of the EBV latent to lytic switch.
authors.affiliation: Department of Molecular Biophysics, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
authors.forename: Derek
authors.initials: D
authors.lastname: Daigle
authors.forename: Cynthia
authors.initials: C
authors.lastname: Megyola
authors.forename: Ayman
authors.initials: A
authors.lastname: El-Guindy
authors.forename: Lyn
authors.initials: L
authors.lastname: Gradoville
authors.forename: David
authors.initials: D
authors.lastname: Tuck
authors.forename: George
authors.initials: G
authors.lastname: Miller
authors.forename: Sumita
authors.initials: S
authors.lastname: Bhaduri-McIntosh
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000187:drug effects / Q000821:virology; D002087:Butyrates / Q000494:pharmacology; D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D004854:Herpesvirus 4, Human / Q000187:drug effects* / Q000502:physiology; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D011817:Rabbits; D050796:STAT3 Transcription Factor / Q000378:metabolism*; D015854:Up-Regulation; D014775:Virus Activation / Q000187:drug effects*; D017735:Virus Latency
chemical_list: D002087:Butyrates; D056572:Histone Deacetylase Inhibitors; D050796:STAT3 Transcription Factor